Article

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer

2025-09-20

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a devastating prognosis. Gemcitabine, a pyrimidine anti-metabolite, is a cornerstone in PDAC therapy. However, resistance remains a major hurdle in clinical care. Resistance can arise from microenvironmental metabolites or through direct metabolic reprogramming of pancreatic cancer cells. Here, we generated PDAC models of acquired gemcitabine resi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 72db90f5-ef1f-578c-907e-c3aa79f122e3
DOI: 10.1101/2025.09.19.675739

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic CancerDOI 10.1101/2025.09.19.675739Read

Targeting Mevalonate Pathway Enhances the efficacy of 5-Fluorouracil by regulating pyroptosisSemantic proximity Read

In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependencySemantic proximity Read

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.Semantic proximity Read

Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic CancerSemantic proximity Read

The biological role of metabolic reprogramming in pancreatic cancerSemantic proximity Read

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic TumorsSemantic proximity Read

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesisSemantic proximity Read

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancerSemantic proximity Read

MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine ResistanceSemantic proximity Read

An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinomaSemantic proximity Read

Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cellsSemantic proximity Read